Tara Sanft, MD

Articles

Dr. Sanft on Sequencing of Treatments for HER2+ Breast Cancer

February 3rd 2017

Tara Sanft, MD, assistant professor of Medicine, medical director of Adult Survivorship for Yale Cancer Center Survivorship Clinic, discusses sequencing of treatments for patients with HER2-positive breast cancer.

Dr. Sanft on Treatment Options in HER2-Positive Breast Cancer

October 18th 2016

Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discusses standard treatment options for patients with HER2-positive breast cancer.

Dr. Sanft on HER2-Positive Breast Cancer

September 21st 2016

Tara Sanft, MD, assistant professor of medicine, medical director of adult survivorship for the Yale Cancer Center Survivorship Clinic, discuses advancements in HER2-positive breast cancer.

Clinical Utility of Emerging Molecular Diagnostics in Breast Cancer

March 9th 2016

The past decade of biomarker research has led to the introduction of several multigene prognostic tests that are now routinely used in clinical decision making to assist the se-lection of patients for adjuvant chemotherapy, and several other tests have emerged with potential clinical utility.

Dr. Sanft on How Survivorship Care Plans Differ Among Patients

May 12th 2015

Tara Sanft, MD, assistant professor of medicine, director, Survivorship Clinic, Smilow Cancer Hospital at Yale-New Haven, discusses survivorship care plans and how they can differ among patients.